Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors.

The role of microenvironment interleukin 1 (IL-1) on 3-methylcholanthrene (3-MCA)-induced carcinogenesis was assessed in IL-1-deficient mice, i.e., IL-1beta(-/-), IL-1alpha(-/-), IL-1alpha/beta(-/-) (double knockout), and mice deficient in the naturally occurring inhibitor of IL-1, the IL-1 receptor antagonist (IL-1Ra). Tumors developed in all wild-type (WT) mice, whereas in IL-1beta-deficient mice, tumors developed slower and only in some of the mice. In IL-1Ra-deficient mice, tumor development was the most rapid. Tumor incidence was similar in WT and IL-1alpha-deficient mice. Histologic analyses revealed fibrotic structures forming a capsule surrounding droplets of the carcinogen in olive oil, resembling foreign body-like granulomas, which appeared 10 days after injection of 3-MCA and persisted until the development of local tumors. A sparse leukocyte infiltrate was found at the site of carcinogen injection in IL-1beta-deficient mice, whereas in IL-1Ra-deficient mice, a dense neutrophilic infiltrate was observed. Treatment of IL-1Ra-deficient mice with recombinant IL-1Ra but not with an inhibitor of tumor necrosis factor abrogated the early leukocytic infiltrate. The late leukocyte infiltrate (day 70), which was dominated by macrophages, was also apparent in WT and IL-1alpha-deficient mice, but was nearly absent in IL-1beta-deficient mice. Fibrosarcoma cell lines, established from 3-MCA-induced tumors from IL-1Ra-deficient mice, were more aggressive and metastatic than lines from WT mice; cell lines from IL-1-deficient mice were the least invasive. These observations show the crucial role of microenvironment-derived IL-1beta, rather than IL-1alpha, in chemical carcinogenesis and in determining the invasive potential of malignant cells.

[1]  E. Voronov,et al.  Interleukin-1--a major pleiotropic cytokine in tumor-host interactions. , 2002, Seminars in cancer biology.

[2]  Stephen M Hewitt,et al.  The role of interleukin 1 in growth and metastasis of human cancer xenografts. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Michael U. Martin,et al.  Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. , 2002, Biochimica et biophysica acta.

[4]  L. O’Neill Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily. , 2002, Current topics in microbiology and immunology.

[5]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Nomura,et al.  Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. , 2004, The Journal of clinical investigation.

[7]  S. Weitzman,et al.  Phagocytes as carcinogens: malignant transformation produced by human neutrophils. , 1985, Science.

[8]  D. Hanahan,et al.  Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells , 2003, The Journal of experimental medicine.

[9]  S. Segal,et al.  CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells1 , 2005, The Journal of Immunology.

[10]  Ryan M. O’Connell,et al.  MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. , 2006, Immunity.

[11]  C. Dinarello,et al.  The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Zöller,et al.  Interleukin‐1 produced by tumorigenic fibroblasts influences tumor rejection , 1992, International journal of cancer.

[13]  C. Garlanda,et al.  Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll‐like receptors: the new entry TIR8/SIGIRR , 2004, Journal of leukocyte biology.

[14]  Y. Ben-Neriah,et al.  Inflammation and cancer: is the link as simple as we think? , 2005, The Journal of investigative dermatology.

[15]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[16]  T. Blankenstein,et al.  Inhibition of Methylcholanthrene-induced Carcinogenesis by an Interferon γ Receptor–dependent Foreign Body Reaction , 2002, The Journal of experimental medicine.

[17]  T. Slaga,et al.  Comparison of the skin tumor initiating activity of 3-methylcholanthrene and 3,11-dimethylcholanthrene in mice. , 1979, Cancer letters.

[18]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[19]  Hans Clevers,et al.  At the Crossroads of Inflammation and Cancer , 2004, Cell.

[20]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[21]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[22]  V. Nizet,et al.  Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer , 2006, Cell.

[23]  J. Leips,et al.  Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression1 , 2006, The Journal of Immunology.

[24]  G. Fantuzzi,et al.  Defective localization of the NADPH phagocyte oxidase to Salmonella-containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Kazuhiro Usui,et al.  Proinflammatory Cytokine IL-1β Promotes Tumor Growth of Lewis Lung Carcinoma by Induction of Angiogenic Factors: In Vivo Analysis of Tumor-Stromal Interaction1 , 2002, The Journal of Immunology.

[26]  Carl Nathan,et al.  Points of control in inflammation , 2002, Nature.

[27]  L. Coussens,et al.  Inflammatory Cells and Cancer , 2001, The Journal of experimental medicine.

[28]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[29]  J. Pollard Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[30]  J. Sims IL-1 and IL-18 receptors, and their extended family. , 2002, Current opinion in immunology.

[31]  C. Dinarello Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. , 2004, Current opinion in pharmacology.

[32]  Y. Ben-Neriah,et al.  NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. , 2003, Seminars in cancer biology.

[33]  N. Fausto,et al.  Impaired Preneoplastic Changes and Liver Tumor Formation in Tumor Necrosis Factor Receptor Type 1 Knockout Mice , 2000, The Journal of experimental medicine.

[34]  C. Dinarello Blocking IL-1 in systemic inflammation , 2005, The Journal of experimental medicine.

[35]  S. Argov,et al.  Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell‐associated IL‐1α , 2006, Journal of leukocyte biology.

[36]  S. Segal,et al.  Differential Effects of IL-1α and IL-1β on Tumorigenicity Patterns and Invasiveness 1 , 2003, The Journal of Immunology.

[37]  S. Hewitt,et al.  Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. , 2003, Cancer research.

[38]  M. Marino,et al.  Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. , 1999, Cancer research.

[39]  Y. Iwakura Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. , 2002, Cytokine & growth factor reviews.

[40]  T. Blankenstein,et al.  Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. , 2003, Advances in cancer research.

[41]  S. Nakae,et al.  Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist–Deficient Mice , 2000, The Journal of experimental medicine.

[42]  F. Balkwill Tumor necrosis factor or tumor promoting factor? , 2002, Cytokine & growth factor reviews.

[43]  P. Szlosarek,et al.  Tumour necrosis factor α: a potential target for the therapy of solid tumours , 2003 .

[44]  S. Nakae,et al.  TNF-alpha is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. , 2004, The Journal of clinical investigation.

[45]  Robert J. Moore,et al.  Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. , 2002, Oncogene.

[46]  Masatoshi Suzuki,et al.  Production of Mice Deficient in Genes for Interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 Receptor Antagonist Shows that IL-1β Is Crucial in Turpentine-induced Fever Development and Glucocorticoid Secretion , 1998, The Journal of experimental medicine.

[47]  Michael T. Lotze,et al.  Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.

[48]  H. Schreiber,et al.  Inflammation as a tumor promoter in cancer induction. , 2004, Seminars in cancer biology.

[49]  M. Zöller,et al.  Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. , 1992, International journal of cancer.

[50]  M. Zöller,et al.  Interleukin‐1 production by transformed fibroblasts. II. Influence on antigen presentation and T‐cell‐mediated anti‐tumor response , 1992, International journal of cancer.